Impact of Diabetes Mellitus and Insulin on Nonalcoholic Fatty Liver Disease in the Morbidly Obese.
CONCLUSION: Type 2 diabetes mellitus plays an important role in the progression of non-alcoholic fatty liver disease as an independent risk factor for severe fibrosis. PMID: 29893699 [PubMed - in process]
A study of more than 90,000 British adults by the University of East Anglia also found that gay men are 28 per cent less likely to be overweight or obese than their straight counterparts.
It is certainly no secret that nutrition in the first few years of life, when growth is rapid, plays a major role in long-term health outcomes in regard to both optimal growth and obesity prevention. Formula fed infants gain weight faster than breastfed infants and weight gain is greater in formula fed infants receiving isocaloric formulas with higher protein content. Although the evidence favors promoting breast milk over formula feedings, there is little evidence-based guidance as to which complementary feeds should be given to promote optimal growth and to prevent obesity.
Geserick M, Vogel M, Gausche R, Lipek T, Spielau U, Keller E, et al. Acceleration of BMI in Early Childhood and Risk of Sustained Obesity. N Engl J Med 2018;379:1303-12.
Kuppermann N, Ghetti S, Schunk JE, Stoner MJ, Rewers A, McManemy JK. Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis. N Engl J Med 2018;378:2275-87.
Conclusions: AWG immediately after PSWG, even occurring at only 1 of 3 interval from 3 –4 to 6–9 months, from 6–9 to 17–20 months, and 17–20 months to 3 years after PSWG, leads to an overweight status at 3 years of age. Monitoring weight growth after PSWG may help identify AWG and later overweight risk.Ann Nutr Metab 2019;74:181 –188
This study examined the risk for postoperative complications, reoperations, and readmissions for patients with insulin-dependent diabetes mellitus (IDDM), patients with non-insulin-dependent diabetes mellitus (NIDDM), and patients without diabetes undergoing total joint replacements (TJRs). The American College of Surgeons National Surgical Quality Improvement Program database was queried for all primary TJRs in 2015. The study identified 78,744 TJRs (84.1% nondiabetic patients, 12.0% NIDDM, and 3.9% IDDM). Multiple logistic regression models identified IDDM as an independent risk factor for increased blood loss, myocardia...
This study sought to characterize the changes in general immunity occurring during the progression from pre-diabetes to T2D. Male rats were fed a high-fat high-carbohydrate diet for 20 weeks (pre-diabetes induction period) and kept on the same diet being monitored for a further 12 weeks (experimental period). Blood was collected for haemocytometer analysis on week 0, 4, 8, and 12 of the experimental period after which the animals were sacrificed. Plasma was collected from centrifuged blood for ELISA (TNF-α, CRP, P-selectin, CD40 L, fibrinogen, and IL-6). Blood neutrophils percentage significantly...
HIGH blood pressure risk could be lowered by making some exercise or lifestyle changes. You could prevent deadly hypertension symptoms, and make your heart stronger, by regularly doing this sport.
Publication date: Available online 19 February 2019Source: Food Quality and PreferenceAuthor(s): Maria Pina Concas, Eulalia Catamo, Ginevra Biino, Daniela Toniolo, Paolo Gasparini, Antonietta RobinoAbstractFood preferences are influenced by a large number of physiological, nutritional, environmental, sociocultural and genetic factors. From previous studies, survey-reported food likings may reflect habitual intake, being cognitively simple to recall than intake, and have associated with risk factor for diet-related diseases.This work was secondary analysis of a large dataset of personal, clinical and lifestyle measures from...
First-line treatment with the anti-PD-1 immunotherapy pembrolizumab plus the VEGF-targeted tyrosine-kinase inhibitor axitinib extended overall survival and progression-free survival in patients with clear-cell metastatic renal cell carcinoma (mRCC), compared with the current standard of care, sunitinib, in the phase 3 KEYNOTE-426 trial.Reuters Health Information
More News: Alcoholism | Bariatric Surgery | Cancer & Oncology | Carcinoma | Cirrhosis | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Gastroenterology | Hepatocellular Carcinoma | Hypertension | Insulin | Laboratory Medicine | Liver | Liver Cancer | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Study | Urology & Nephrology